Summary of HR 5629: Medications for the Treatment of Opioid Use Disorder

Bill Overview

Bill Number: HR 5629

Introduced On: September 30, 2025

Status: Introduced in House

Primary Sponsor: Erin Houchin

The purpose of HR 5629 is to nullify the final rule issued by the Department of Health and Human Services (HHS) concerning medications for the treatment of opioid use disorder, with a specific exception regarding the accreditation of opioid treatment programs.

Key Provisions

• Nullification of Final Rule:
  
  The bill states that the final rule titled "Medications for the Treatment of Opioid Use Disorder," published in the Federal Register on February 2, 2024, shall have no force or effect. This rule includes various regulations and guidelines aimed at managing the treatment of individuals with opioid use disorder.

• Exception for Accreditation:
  
  The only portion of the final rule that will remain in effect is the section that pertains to modifications of subpart B of part 8 of title 42 of the Code of Federal Regulations, which relates specifically to the accreditation of opioid treatment programs. This means that while most of the new regulations will be rescinded, the standards for accrediting treatment programs will still apply.

Impact

• Affected Entities:
  
  The bill primarily impacts healthcare providers, treatment facilities, and patients involved in opioid use disorder treatment. By nullifying the majority of the final rule, it may affect the availability and regulation of medications used in treatment, potentially altering how treatment programs operate.

• Regulatory Environment:
  
  The bill aims to revert the regulatory landscape back to pre-rule conditions for most aspects of opioid treatment, which could lead to changes in how treatment is administered and monitored.

Legislative Process

• Committee Referral:
  Upon introduction, HR 5629 was referred to the House Committee on Energy and Commerce for further consideration. This committee will review the bill and may hold hearings or discussions before it is brought to the floor for a vote.

Conclusion

HR 5629 seeks to repeal significant portions of the HHS final rule on opioid use disorder treatment, with the exception of accreditation standards for treatment programs. The bill reflects ongoing legislative efforts to address the opioid crisis and the regulatory framework surrounding treatment options. As it progresses through the legislative process, its implications for treatment providers and patients will be closely monitored.